Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QVM149 versus salmeterol + fluticasone in adolescents with asthma
2022-502365-26-00Phase 3Authorised
- Sponsor
- Novartis
- Start
- Aug 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial of indacaterol acetate + glycopyrronium bromide + mometasone furoate and salmeterol + fluticasone in asthma (2 arms), sponsored by Novartis. Primary endpoint: Change from baseline in trough FEV1 at Week 12 of each treatment period. Planned start Aug 2026; status: authorised.
02
Drugs
indacaterol acetate + glycopyrronium bromide + mometasone furoatesalmeterol + fluticasone
03
Conditions
asthma
Beyond the preview
Go deeper on 2022-502365-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502365-26-00.